These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31049148)

  • 21. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?
    Rosenson RS
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):777-82. PubMed ID: 26966281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
    Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE;
    N Engl J Med; 2017 May; 376(20):1933-1942. PubMed ID: 28514624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anacetrapib: a potential new therapy for dyslipidemia.
    Robinson LB; Frishman WH
    Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 25. High density lipoprotein - should we raise it?
    Landmesser U
    Curr Vasc Pharmacol; 2012 Nov; 10(6):718-9. PubMed ID: 23259564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
    Eyvazian VA; Frishman WH
    Cardiol Rev; 2017; 25(2):43-52. PubMed ID: 28099220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
    Doggrell SA
    Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. It's never too early to beat your low-density lipoprotein cholesterol.
    Bergerot C; Angoulvant D; Lemesle G; Barone-Rochette G; Mewton N; Mach F
    Arch Cardiovasc Dis; 2021 Jan; 114(1):1-3. PubMed ID: 33509745
    [No Abstract]   [Full Text] [Related]  

  • 32. AHA/ACC/Multisociety Cholesterol Guidelines: highlights.
    Jialal I; Devaraj S
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719881579. PubMed ID: 31590600
    [No Abstract]   [Full Text] [Related]  

  • 33. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
    Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.
    Rhainds D; Tardif JC
    Curr Opin Lipidol; 2019 Apr; 30(2):101-107. PubMed ID: 30672808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should we take high-density lipoprotein cholesterol levels at face value?
    Leite JO; Fernandez ML
    Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.
    Navarese EP; Andreotti F; Raggi P; Kolodziejczak M; Buffon A; Bliden K; Tantry U; Kubica J; Sardella G; Lauten A; Agewall S; Gurbel PA; Brouwer MA
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):47-54. PubMed ID: 30247574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.